Company Encyclopedia
View More
name
Berry Genomics
000710.SZ
Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor genetic testing, NextSeq CN500 gene sequencer, and laboratory solutions. It also provides technology services, such as human genome sequencing, transcriptional regulation, single cell/spatial sequencing, animal and plant genome resequencing, genome denovo sequencing, and microbial sequencing, as well as big data services. The company serves various organizations and facilities, including hospitals, research institutions, universities, and enterprises throughout Mainland China, Hong Kong, Macao, Taiwan, Southeast Asia, the Middle East, and Australia.
1.579 T
000710.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking73/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-14.62%E
    • Profit Margin-27.13%E
    • Gross Margin49.02%B
  • Growth ScoreD
    • Revenue YoY-15.09%E
    • Net Profit YoY9.39%C
    • Total Assets YoY-7.71%D
    • Net Assets YoY-13.56%E
  • Cash ScoreE
    • Cash Flow Margin-368.54%D
    • OCF YoY-15.09%E
  • Operating ScoreC
    • Turnover0.39C
  • Debt ScoreB
    • Gearing Ratio29.63%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Berry Genomics' subsidiary's third-generation gene sequencer Sequel®II CNDx has obtained a medical device registration certificate

    Berry Genomics' wholly-owned subsidiary, Hangzhou Berry Health Gene Diagnostic Technology Co., Ltd., has recently obtained the medical device registration certificate from the National Medical Products Administration for its third-generation gene sequencer Sequel® II CNDx. This is the world's first third-generation gene sequencing platform approved for clinical application, capable of accelerating sample processing and reporting cycles, thereby improving in-hospital service quality. Berry Genomics has achieved independent production of third-generation sequencing supporting detection reagents, promoting domestic technological achievements to advance globally

    Zhitong·
    SZ
    000710
    +1.57%
    Zhitong·
    SZ
    000710
    +1.57%

    Berry Genomics released its performance for the first three quarters, with a net loss attributable to the parent company of 52.5637 million yuan

    According to the Zhitong Finance APP, Berry Genomics released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 686 million yuan, a year-on-year decrease of 16.65%. The net loss attributable to shareholders of the listed company was 52.5637 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 53.7914 million yuan

    Zhitong·
    SZ
    000710
    +1.57%
    Zhitong·
    SZ
    000710
    +1.57%

    Berry Genomics: Net loss of RMB 25.3212 million in the third quarter, a decrease of 2,355.45%

    Berry Genomics announced that its revenue for the third quarter was 238 million yuan, a decrease of 12.06%; the net profit loss was 25.3212 million yuan, a decrease of 2,355.45%. Revenue for the first three quarters was 686 million yuan, a decrease of 16.65%; the net profit loss was 52.5637 million yuan, a decrease of 606.13%

    Zhitong·
    SZ
    000710
    +1.57%
    Zhitong·
    SZ
    000710
    +1.57%

    Berry Genomics controlling shareholder's concerted action on 40,000 shares judicial auction failed to sell

    Chengdu Berry Genomics Co., Ltd. announced that 400,000 shares of the company's stock held by its controlling shareholder's concerted actor, Hou Ying, failed to sell at judicial auction on September 12, 2025. This share represents 100% of his holdings and 0.11% of the company's total share capital. As of the announcement date, a total of 19,805,661 shares held by Hou Ying have been subject to judicial auction. The company's production and operations are normal, and this auction has not had a significant adverse impact; the unsold shares will be disposed of according to the court's ruling

    Zhitong·
    SZ
    000710
    +1.57%
    Zhitong·
    SZ
    000710
    +1.57%

    Berry Genomics plans to hold a controlling stake in YiYuan TongKang to provide integrated testing services for genetic diseases in newborns and children

    Berry Genomics announced that its wholly-owned subsidiary, Berry Health, plans to establish a holding subsidiary, YiYuan TongKang, with Mr. Li Wei in Zhengzhou, with a registered capital of 1 million yuan, in which Berry Health will hold 60%. The company will collaborate with public medical institutions to provide genetic disease testing services for newborns and children, with the future registered capital expected to be no less than 50 million yuan

    Zhitong·
    SZ
    000710
    +1.57%
    Zhitong·
    SZ
    000710
    +1.57%
    © 2025 Longbridge｜Disclaimer